Inflammatory Myofibroblastic Tumor of Genitourinary Tract Beyond Collecting System

A Rare Case Report With Literature Review

Ling-Fan Xu, MD, Jun Zhou, MD, and Chao-Zhao Liang, MD, PhD

Abstract: Inflammatory myofibroblastic tumor (IMT) rarely arises in genitourinary tract especially beyond collecting system, which determines the unspecific clinic symptoms and sometimes can mimic malignancy. Therefore, IMT’s diagnosis may usually be a pitfall. This case report characterizes a 35-year-old woman with a history of lower quadrant lasting pain followed by fever. Furthermore, radiologic examinations revealed that there were 2 lesions located in left adrenal area and left renalis. Owing to the anatomic complexity, the surgical resection was not complete. The pathologic diagnosis of the lesions was IMT. Adjuvant nonsteroids anti-inflammatory drugs were administrated after the operation. The symptoms were controlled finally and no further growing lesion was observed during a 1-year follow-up.

Inflammatory myofibroblastic tumor is rare in genitourinary tract beyond the collecting system. Diagnosis should be based on histopathology. Presently, the authors report this rare case with the aim to share the experience regarding differential diagnosis and therapy.

Editor: Miao Liu.
Received: June 21, 2015; revised: September 2, 2015; accepted: September 9, 2015.
From the Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China (LFX, JZ, C-ZL).
Correspondence: Chao-Zhao Liang. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China (e-mail: liang_chaozhao@163.com).
LFX and JZ, these authors contributed equally to this work.
Author contributions LFX, JZ, and C-ZL contributed to the operation. LFX contributed to drafting the manuscript.
This work was supported by The First Affiliated Hospital of Anhui Medical University.
The authors have no conflicts of interest to disclose.
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000001706

INTRODUCTION

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor of unknown etiology and pathogenesis composed of neoplastic myofibroblasts with inflammatory infiltrate, which can arise in multiple anatomic locations. Therefore, the patients often exhibit highly variable and unpredictable clinical behaviors. For adults, IMT mainly initiates in respiratory and alimentary systems, such as lung, liver, colon, spleen, pancreas, etc.1–3 By contrast, IMT seldom occurs in the genitourinary tract and most of the ones that have been reported are urinary bladder and prostate lesions.4

Herein, we present a special case of a 35-year-old woman with adrenal area and renalis IMT, which, to the best of our knowledge, have hardly been reported in other medical institutions.

CASE REPORT

A 35-year-old woman was initially admitted to our department on June 15, 2014 (The First Affiliated Hospital of Anhui Medical University) with a 1-month history of lasting pain in left lower quadrant of abdomen, which exacerbated at night. Furthermore, case history was noncontributory, such as gross hematuria, dysuria, nausea, vomit, etc.

Contrast-enhanced computed tomography of abdomen revealed 2 conspicuous unclear border masses located in the left adrenal area and left renalis of approximately 4.5 cm × 3 cm and 3 cm × 2 cm, respectively (Fig. 1A-B).

After admission, the patient’s body temperature became ascending and the highest was 39.8 °C. We, however, could not find any relevant infectious factors. The whole blood culture results were negative. Considering the symptoms and radiologic presentations, the first clinical impression was malignant lymphoma.

On June 17, we undertook a surgical resection. Because the renalis mass adjacent to the renal artery, which could not be separated, we excised the whole mass in left adrenal area meanwhile resected the renalis mass as much as possible to make clear the pathologic character of the lesions.

The histopathologic examination of the masses demonstrated an abnormal proliferation of spindle cells in a fascicular and myxoid pattern with no significant nuclear atypia accompanied by inflammatory cells, including lymphocytes, eosinophils, and plasma cells. The immunohistochemical stains illustrated that spindle cells were positive for anaplastic lymphoma kinase (ALK), smooth muscle actin (SMA), calponin, and vimentin whereas negative for CD15, CD23, CD30, CD34, creatinine kinase, or leukocyte common antigen (Fig. 2A-E).

In postoperative period, we treated the patient with adjuvant nonsteroids anti-inflammatory drugs (NSAIDs). Following the diclofenac sodium and lidocaine hydrochloride injection therapy (95 mg/d, administered intramuscular injection for the first 3 days), the patient’s clinical symptoms improved. She was subsequently kept on the oral substitution for another week (50 mg of diclofenac sodium enteric-coated tablets per day). The body temperature gradually turned normal and the patient recovered uneventfully. Frequent re-examinations were required. During the most recent follow-up in March 2015, the woman remained healthy and fit without any uncomfortable symptoms.
complains and we could not find any neonatal lesions from the radiologic examination compared with the former one.

**DISCUSSION**

Inflammatory myofibroblastic tumor is an unusual spindle cell proliferative lesion, which was first reported by Brunn et al\(^5\) on 2 cases of “myoma of the lung” in 1939, and thus, in general, it is classified under the pulmonary and extrapulmonary sites category.\(^6\) During the last 50 years, IMT has been attributed to numerous nomenclature, such as inflammatory pseudotumor, pseudosarcomatous myofibroblastic, fibromyxoid lesion, plasma cell granuloma.\(^4\) Inflammatory myofibroblastic tumor, however, has been identified because its histopathologic features have been revealed gradually. Although the exact pathogenesis remains unknown, all these lesions share the key pathologic differentiation: a variety of inflammatory cells, plasma cells, and/or lymphocytes accompany with a dominant spindle cell proliferation, which have been demonstrated as myofibroblasts, according to the World Health Organization in 1994.\(^4\)

The histologic presentation of IMT may range broadly from tumors at different anatomic sites to those at the same site. Three typical appearances have been described: myofibroblasts surrounded by a stellate or spindled appearance, which are mainly found in the genitourinary; more densely packed stromal cells interspersed with an inflammatory component, which may show focal nodular lymphoid hyperplasia; and hypocellular stroma.\(^4\) These 3 patterns can either mix in 1 tumor or exhibit independently. In a previous systematic review by Teoh et al\(^8\), the myxoid or vascular pattern took up a considerable proportion, with the figure standing at 83.8%, of the total number of all the IMT patients. The fibrous hypocellular pattern occupied the smallest percentage, which accounted 5.9%. And the compact spindle cell pattern contributed 55.9%. Approximately, 41.2% of the total patients had mixed histologic patterns. Intermingling bundles of fibrocollagenous tissue and inflammatory cells were shown in our case, which supported the IMT diagnosis.

Although the morbidity of IMT has a wide spectrum of ages (between 7 days and 88 years) in both sexes, it is more frequently seen in youths and has a sex predilection for female.\(^9\) Studies have shown that it is rare to find IMT in genitourinary tract, let alone kidney, urethra, ureter, and prostate. Furthermore, among those cases, most arise in urinary bladder.\(^10\) The most common symptom is painless hematuria either with or without clots. Others include abdominal or pelvic pain, dysuria, and infection.\(^10\) Systemic symptoms, such as fever and weight loss are seldom observed in clinic. Owing to the lacking of specific clinical symptoms and radiologic examinations, the clinical diagnosis of IMT is quite difficult. In this case, the primary symptom of the patient was fever, rather than any urinary system discomfort. The temperature type is intermittent fever. In addition, the contrast-enhanced computed tomography examination indicated 2 unclear border masses located in adrenal area and renalis, respectively. These features were very similar to the performance of malignant lymphoma cases that we had observed before. Therefore, malignant lymphoma emerged as the first clinic impression.

As we know, all the tumor’s attributes should be diagnosed by histologic examination, certainly, including IMT. Unfortunately, the differential is not distinct because the overlapping of inflammatory pseudotumor, pseudosarcomatous myofibroblastic, or fibromyxoid lesion, plasma cell granuloma, especially the postoperative spindle cell nodule, which runs a benign reactive myofibroblastic proliferation of the genitourinary tract that arises exclusively after instrumentation, usually a surgical procedure such as transurethral resection of bladder tumor.\(^11\) In the recent 15 years, the consequence of ALK expressed in IMT has made it a relative distinct entity when it comes to immunohistochemical and molecular characteristics.\(^8\) Anaplastic lymphoma kinase rearrangements were first reported in the anaplastic large cell lymphoma, and Cessna et al\(^12\) described that more than 40% IMT patients had the abnormalities of chromosome 2p23 with expression of ALK and p80. These genetic bases demonstrate that IMT is neoplastic rather than simply reactive in nature. It also makes ALK a hallmark for IMT histologic diagnosis. Besides, previous literature have
demonstrated that the spindle cells of IMT reacted immuno-
histochemically with vimentin, calponin, and SMA but were
usually negative for desmin.13 Qiu et al14 reported that among
the 18 IMT patients, the proportion of expression of calponin
and SMA were 100 and 94%, respectively, whereas desmin
expressed less frequently (7/21, 33%). Similarly, in a case of a
9-month-old boy with mesenteric IMT, Buccoliero et al15 found
that the tumor cells were positive for vimentin whereas negative
for CD34 and S100 protein. Generally, the lesions are negative
for CD15, CD34, CD117 (c-kit), etc.16 As illustrated in both the
current series and others, it, however, is not always possible to
identify SMA, calponin, and vimentin positivity or positivity
for other markers of myofibroblastic differentiation. Many
factors (eg, age, anatomic site, etc.) may result in different
expressions.17 In our case, the spindle cells were positive for
ALK, vimentin, calponin, and SMA, all of which confirmed the
IMT diagnosis in histologic aspect and it was considered as a
mixed pattern from its histologic features.

Owing to the fact that IMT has been confirmed in a
spectrum of anatomic locations, there are various treatment
modalities, including surgery, steroids, NSAIDs, radiotherapy,
and chemotherapy. Of these treatments, surgical resection
remains the priority for all the IMT lesions if not prohibited
by anatomic location. The role of chemotherapy and radiation
therapy is unclear upon the limited experience. Dishop et al18
reported a pediatric IMT patient received chemotherapy, and
was tumor free in the 2 years following the incomplete surgical
resections. Radiation therapy has been suggested to be effective
to a certain degree in pulmonary IMT, according to Imperato
et al.19 If complete resection is not possible, the alternatives of
chemotherapy combined with radiation therapy, typically
biopsy or observation could be taken into consideration. Steroids
and NSAIDs may be regarded as an adjuvant approach
to reducing the surrounding inflammation. There are several
case reports of IMT being successfully treated with NSAIDs.20–
22 According to Applebaum et al,23 because IMTs are composed
of organized vasculature and inflammatory tissue admixed with
myofibroblasts, and the identification of a substantial presence of
vascular endothelial growth factor (VEGF) and cyclooxygenase
2 (Cox-2) enzyme in IMTs, they hypothesized that NSAIDs can
be applied to these masses to disrupt the angiogenesis, specifi-
cally by interfering with VEGF signaling via Cox-2 inhibition.
in their study, all the samples are positive of VEGF and Cox-2
immunostaining, supporting the idea that interference with Cox-
2 angiogenic pathway is a possible strategy. The diclofenac
sodium and lidocaine hydrochloride injection, consisted of
diclofenac sodium (75 mg) and lidocaine hydrochloride
(20 mg), is a Cox-2 inhibitor that has been widely used in clinic
to reduce the inflammation. In our case, because of the anatomic
complexity, a complete resection of the 2 masses was not possible.
In the postoperative stage, we treated the patient with
the diclofenac sodium and lidocaine hydrochloride injection as
part of the adjuvant therapy. It finally came with an exciting
result. The symptom disappeared and the patient was back to a
normal life. A close follow-up was undergoing and the rest of
the mass was not growing.

Although IMT rarely processes metastasis, Coffin et al24
demonstrated that the recurrence happened in approximately
25% of IMT patients and particularly when the lesions were
extrapulmonary. In addition, because IMT has been reported to
exhibit aggressive local behavior and locally destructive var-
iants, a close follow-up is highly recommended, especially for
the patients whose lesions cannot be operatively extirpated
completely.

**CONCLUSIONS**

From the current case, we demonstrate that although IMT
is rare in genitourinary tract, it can still be found even in renalis
and adrenal area. Diagnosis of IMT can be misled to other
system diseases such as malignant lymphoma because of its
atypical appearances. A definitive diagnosis should depend on
histopathology. Complete excision should be considered firstly
for localized lesion as long as the functional and anatomic
conditions are acceptable. Whereas, on condition that the
surgical resection is not satisfactory, steroids and NSAIDs
may be used to control the surrounding inflammation to achieve the maximum clinical efficacy. Meanwhile, a long-term follow-up and close surveillance are indispensable according to its histologic resemblance to certain malignant tumors.

**Ethics Statement**

Informed consents were signed by this patient and the investigation was evaluated thoroughly and then approved strictly according to the regulations by the Ethics Committees on Human Research of The First Affiliated Hospital of Anhui Medical University (Approval No. PJ20150808).

**REFERENCES**

1. Tuncöguir B, Ustünsoy H, Bakır K, et al. Inflammatory pseudotumor of the lung. *Thorac Cardiovasc Surg.* 2000;48:112–113.
2. Liu TH, Consorti ET. Inflammatory pseudotumor presenting as a cystic tumor of the pancreas. *Am Surg.* 2000;66:993–997.
3. Koea JB, Broadhurst GW, Rodgers MS, et al. Inflammatory pseudotumor of the liver: demographics, diagnosis, and the case for nonoperative management. *J Am Coll Surg.* 2003;196:226–235.
4. Kovach SJ, Fischer AC, Katzman PJ, et al. Inflammatory myofibroblastic tumors. *J Surg Oncol.* 2006;94:385–391.
5. Brunn H. Two interesting benign lung tumors of contradictory histopathology. *J Thorac Surg.* 1939;9:119–131.
6. Anthony PP. Inflammatory pseudotumour (plasma cell granuloma) of lung, liver and other organs. *Histopathology.* 1993;23:501–503.
7. Coindre JM. Histologic classification of soft tissue tumors (WHO, 1994). *Annales de Pathologie.* 1994;14:426–427.
8. Teoh JYC, Chan NH, Cheung HY, et al. Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review. *Urology.* 2014;84:503–508.
9. Yagnik V, Chadha A, Chaudhari S, et al. Inflammatory myofibroblastic tumor of the urinary bladder. *Urol Ann.* 2010;2:78–79.
10. Cheng L, Foster SR, MacLennan GT, et al. Inflammatory myofibroblastic tumors of the genitourinary tract: single entity or continuum? *J Urol.* 2008;180:1235–1240.
11. Alderman M, Kunju LP. Inflammatory myofibroblastic tumor of the bladder. *Arch Pathol Lab Med.* 2014;138:1272–1277.
12. Cessna MH, Zhou H, Sanger WG, et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. *Mod Pathol.* 2002;15:931–938.
13. Rd FA, Mark EJ, Kradin RL. Pulmonary “inflammatory myofibroblastic” tumors: a critical examination of the diagnostic category based on quantitative immunohistochemical analysis. *Virchows Arch.* 2007;450:585–590.
14. Qiu X, Montgomery E, Sun B. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibrolasts. *Hum Pathol.* 2008;39:846–856.
15. Buccoliero AM, Ghionzoli M, Castiglione F, et al. Inflammatory myofibroblastic tumor: clinical, morphological, immunohistochemical and molecular features of a pediatric case. *Pathol Res Pract.* 2014;210:1152–1155.
16. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. *Am J Surg Pathol.* 2007;31:509–520.
17. Nonaka D, Birbe R, Rosai J. So-called inflammatory myofibroblastic tumor: a proliferative lesion of fibroblast reticulum cells? *Histopathology.* 2005;46:604–613.
18. Dishop MK, Warner BW, Dehner LP, et al. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy. *J Pediatr Hematol Oncol.* 2003;25:153–158.
19. Imperato JP, Folkman J, Sagerman RH, et al. Treatment of plasma cell granuloma of the lung with radiation therapy. A report of two cases and a review of the literature. *Cancer.* 1986;57:2127–2129.
20. Berger A, Kim C, Hagstrom N, et al. Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy. *Urology.* 2007;70:372e13-5.
21. Kusunoki-Nakamoto F, Matsukawa T, Tanaka M, et al. Successful treatment of an unresectable inflammatory myofibroblastic tumor of the frontal bone using a cyclooxygenase-2 inhibitor and methotrexate. *Intern Med.* 2013;52:623–628.
22. Johnson K, Notrica DM, Carpentieri D, et al. Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib. *J Pediatr Hematol Oncol.* 2013;35:414–416.
23. Applebaum H, Kieran MW, Cripe TP, et al. The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children’s Oncology Group study. *J Pediatr Surg.* 2005;40:999–1003.
24. Coffin CM, Watterson J, Priest JR, et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. *Am J Surg Pathol.* 1995;19:859–872.